Laparoscopic Ultrasound-Guided Removal of Multiple Uterine Fibroids
Laparoscopic Ultrasound-Guided Laparoscopic Myomectomy for Multiple Uterine Fibroids: A Prospective Randomized Controlled Trial
This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.
The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.
The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.
Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.
調査の概要
状態
条件
詳細な説明
Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.
Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.
Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Xiali Xiong
- 電話番号:+86-13520418824
- メール:xiongxiali2009@163.com
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100024
- Beijing Chao Yang Hospital, Capital Medical University
-
コンタクト:
- Xiali Xiong
- 電話番号:+86-13520418824
- メール:xiongxiali2009@163.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Symptomatic multiple uterine fibroids causing symptoms such as abnormal uterine bleeding, anemia, or pressure symptoms, with an indication for laparoscopic myomectomy and a desire to preserve the uterus.
- Diagnosis established through clinical evaluation, preoperative transvaginal ultrasound, and magnetic resonance imaging (MRI), with MRI used for the final assessment and fibroid count.
- Age 20 to 50 years and premenopausal, with or without future fertility plans.
- No contraindications to laparoscopic surgery.
Exclusion Criteria:
- Concomitant submucosal fibroids classified as FIGO types 0-2.
- Findings suspicious for malignancy on preoperative assessment.
- Uterine size equivalent to 20 weeks of gestation or greater; a history of pelvic inflammatory disease; severe endometriosis; grade III or IV uterine prolapse; or a history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, or surgery for pelvic or abdominal tumors.
- Known severe hepatic or renal dysfunction.
- Known hematological disorders, bleeding or coagulation disorders, active bleeding at any site, or a bleeding tendency.
- Severe central nervous system, cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine or metabolic, musculoskeletal, or psychiatric disorders. Endocrine or metabolic disorders include thyroid disease, Cushing's syndrome, and hyperprolactinemia.
- Acute infection.
- Inability to sign the informed consent form.
- Known or suspected poor adherence that would prevent completion of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Laparoscopic Ultrasound-Guided Myomectomy
Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal. |
During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety. |
|
アクティブコンパレータ:Conventional Laparoscopic Myomectomy
Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. |
Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fibroid Removal Rate
時間枠:During surgery and within 3 months after surgery
|
For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100. |
During surgery and within 3 months after surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Operative Time
時間枠:During surgery
|
Duration of the surgical procedure, measured in minutes. |
During surgery
|
|
Residual Uterine Fibroid Rate
時間枠:3 months after surgery (+/- 14 days)
|
Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100. |
3 months after surgery (+/- 14 days)
|
|
Difference Between Removed and Preoperatively Identified Fibroid Counts
時間枠:Preoperative assessment and during surgery
|
For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging. |
Preoperative assessment and during surgery
|
|
Estimated Intraoperative Blood Loss
時間枠:During surgery
|
Estimated volume of blood lost during surgery, measured in milliliters. |
During surgery
|
|
Participants With Intraoperative Complications
時間枠:During surgery
|
Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury. |
During surgery
|
|
Participants With Postoperative Complications
時間枠:From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
|
Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits. |
From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
|
|
Postoperative Length of Hospital Stay
時間枠:Perioperative
|
Time from completion of surgery to hospital discharge, measured in days. |
Perioperative
|
|
Postoperative Pain Score
時間枠:2 and 6 hours after surgery
|
Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain. |
2 and 6 hours after surgery
|
|
Time to First Postoperative Ambulation
時間枠:Perioperative
|
Time from completion of surgery to first postoperative ambulation, measured in hours. |
Perioperative
|
|
Time to First Postoperative Flatus
時間枠:Perioperative
|
Time from completion of surgery to first passage of flatus, measured in hours. |
Perioperative
|
|
Duration of Postoperative Uterotonic Treatment
時間枠:Perioperative
|
Duration of postoperative uterotonic medication use, measured in hours. |
Perioperative
|
|
Time to Postoperative Drain Removal
時間枠:Perioperative
|
Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed. |
Perioperative
|
|
Participants With Postoperative Urinary Dysfunction
時間枠:1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit. |
1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
|
Participants With Postoperative Bowel Dysfunction
時間枠:1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit. |
1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
|
Change From Baseline in Female Sexual Function Index Score
時間枠:Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function. |
Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
|
Change From Baseline in Oswestry Disability Index Score
時間枠:Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability. |
Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
|
Change From Baseline in Zung Self-Rating Anxiety Scale Score
時間枠:Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety. |
Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
|
15-Item Quality of Recovery Questionnaire Score
時間枠:Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated. |
Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2026-sci-844-1
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
There is no plan to share de-identified individual participant data with researchers outside the study team.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。